JP2021510695A5 - - Google Patents

Info

Publication number
JP2021510695A5
JP2021510695A5 JP2020538573A JP2020538573A JP2021510695A5 JP 2021510695 A5 JP2021510695 A5 JP 2021510695A5 JP 2020538573 A JP2020538573 A JP 2020538573A JP 2020538573 A JP2020538573 A JP 2020538573A JP 2021510695 A5 JP2021510695 A5 JP 2021510695A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020538573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510695A (ja
JP7538040B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013315 external-priority patent/WO2019140272A1/en
Publication of JP2021510695A publication Critical patent/JP2021510695A/ja
Publication of JP2021510695A5 publication Critical patent/JP2021510695A5/ja
Priority to JP2023127398A priority Critical patent/JP7817214B2/ja
Application granted granted Critical
Publication of JP7538040B2 publication Critical patent/JP7538040B2/ja
Priority to JP2025061337A priority patent/JP2025106370A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020538573A 2018-01-12 2019-01-11 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物 Active JP7538040B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023127398A JP7817214B2 (ja) 2018-01-12 2023-08-03 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
JP2025061337A JP2025106370A (ja) 2018-01-12 2025-04-02 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862617134P 2018-01-12 2018-01-12
US201862616768P 2018-01-12 2018-01-12
US62/616,768 2018-01-12
US62/617,134 2018-01-12
US201862728514P 2018-09-07 2018-09-07
US62/728,514 2018-09-07
PCT/US2019/013315 WO2019140272A1 (en) 2018-01-12 2019-01-11 Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127398A Division JP7817214B2 (ja) 2018-01-12 2023-08-03 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物

Publications (3)

Publication Number Publication Date
JP2021510695A JP2021510695A (ja) 2021-04-30
JP2021510695A5 true JP2021510695A5 (cg-RX-API-DMAC7.html) 2022-01-18
JP7538040B2 JP7538040B2 (ja) 2024-08-21

Family

ID=65324563

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538573A Active JP7538040B2 (ja) 2018-01-12 2019-01-11 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
JP2023127398A Active JP7817214B2 (ja) 2018-01-12 2023-08-03 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
JP2025061337A Pending JP2025106370A (ja) 2018-01-12 2025-04-02 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023127398A Active JP7817214B2 (ja) 2018-01-12 2023-08-03 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
JP2025061337A Pending JP2025106370A (ja) 2018-01-12 2025-04-02 CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物

Country Status (6)

Country Link
US (3) US11718642B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706761A3 (cg-RX-API-DMAC7.html)
JP (3) JP7538040B2 (cg-RX-API-DMAC7.html)
MA (1) MA51568A (cg-RX-API-DMAC7.html)
TW (2) TW202612704A (cg-RX-API-DMAC7.html)
WO (1) WO2019140272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN111233815B (zh) * 2020-01-21 2022-10-14 上海应用技术大学 一种异阿根廷蚁素的制备方法
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN109503694A (zh) 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
IL312610B2 (en) 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
CN113272315B (zh) 2018-12-26 2023-08-08 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Similar Documents

Publication Publication Date Title
JP2023119042A5 (cg-RX-API-DMAC7.html)
JP2022510683A5 (cg-RX-API-DMAC7.html)
JP2022534424A5 (cg-RX-API-DMAC7.html)
JP2022504607A5 (cg-RX-API-DMAC7.html)
JP2023537632A5 (cg-RX-API-DMAC7.html)
JP2018502891A5 (cg-RX-API-DMAC7.html)
JP2017531020A5 (cg-RX-API-DMAC7.html)
JP2022538300A5 (cg-RX-API-DMAC7.html)
JP2023531517A5 (cg-RX-API-DMAC7.html)
JP2022514385A5 (cg-RX-API-DMAC7.html)
JP2022538301A5 (cg-RX-API-DMAC7.html)
JP2018505898A5 (cg-RX-API-DMAC7.html)
JP2019520417A5 (cg-RX-API-DMAC7.html)
RU2009133259A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2020502092A5 (cg-RX-API-DMAC7.html)
NZ724602A (en) Ror-gamma modulators and uses thereof
JP2023518411A5 (cg-RX-API-DMAC7.html)
IL92558A (en) 4-amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl) pyrimidine and pharmaceutical compositions containing it
JP2009526831A5 (cg-RX-API-DMAC7.html)
ES2711425T3 (es) Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
JP2021512098A5 (cg-RX-API-DMAC7.html)
RU2008107733A (ru) Ингибиторы gsk-3
JP2024520654A5 (cg-RX-API-DMAC7.html)
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
JP2015522606A5 (cg-RX-API-DMAC7.html)